About Us
Executive Director, Chief Executive Officer: Mr. Eric Tse
-
- Executive Director, Chief Executive Officer: Mr. Eric Tse
- He has served as an Executive Director of Sino Biopharmaceutical Limited since 2019, Chairman of CTTQ Pharma since 2020, and has been the Chief Executive Officer of Sino Biopharmaceutical Limited and Chairman of Beijing Tide Pharmaceutical Co., Ltd. since 2022. He holds a Bachelor's degree in Economics from the Wharton School of the University of Pennsylvania, a Master's degree in Management from Schwarzman College at Tsinghua University, and is a Ph.D. candidate in Social and Administrative Pharmacy at China Pharmaceutical University. He was awarded the "Top 10 Outstanding Chinese American Youth" and "Advanced Individual for Outstanding Contribution to Jiangsu Manufacturing".
Mr. Eric Tse is currently a member of the Beijing Municipal Committee of the CPPCC, a member of the 13th National Committee of the All-China Youth Federation, Vice Chairman of the 12th Committee of the Shaanxi Youth Federation, a member of the 7th Election Committee of the Hong Kong SAR, Vice President of the Hong Kong CPPCC Youth Association, a member of the Digital Economy Committee of the APEC China Business Council, a member of the Presidium of Global Shapers under the World Economic Forum, Vice Chairman of the Science and Technology Innovation Committee of the Belt and Road General Chamber of Commerce, a member of the Y.Elites Association, and Executive Vice President of the Jiangsu Overseas Chinese Entrepreneurs Association.
Since taking over as Chief Executive Officer of Sino Biopharm, Mr. Eric Tse has focused on the four major strategies of "organizational integration, comprehensive innovation, internationalization, and digitalization". He oversees the Group's daily operations, advances major decisions on corporate strategy, personnel appointments, and investment integration, and comprehensively manages the Group's subsidiary member companies. He is building a professional management team to further enhance organizational efficiency, drive innovative business, link external cooperation, and advance the Group's global innovation process, committed to building an international innovative pharmaceutical company of China.
Mr. Eric Tse leads the company in unswervingly following the path of innovation and transformation, and building long-term core competitive advantages through comprehensive innovation. Sino Biopharm and its subsidiaries, such as Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Beijing Tide Pharmaceutical Co., Ltd., uphold the mission of "improving the quality of life and protecting the dignity of human life". Guided by societal clinical medication needs, they focus on the four major areas of oncology, hepatology, respiratory, and surgery/analgesic. They advance internal innovation and business development in parallel, cultivate a new innovation ecosystem, shape world-leading innovative R&D capabilities, enhance the Group's core competitiveness with new quality productive forces, and continuously achieve outstanding accomplishments and innovative breakthroughs.
Under the leadership of Eric Tse, the proportion of R&D investment in innovative drugs at Sino Biopharmaceutical Limited has increased to over 80% of total R&D spending. The company has proactively invested in multiple new targets, new platforms, and new technologies with blockbuster potential. In the next three years, more than 10 innovative drugs are expected to be launched to serve patients. Leveraging the strong platform of Sino Biopharm, its subsidiaries Chia Tai Tianqing and Beijing Tide Pharmaceutical have developed steadily. For many consecutive years, they have been selected for authoritative industry lists such as the Top 100 Pharmaceutical Companies in China and the Best Industrial Enterprises for Pharmaceutical R&D Pipelines in China. They have undertaken more than 80 national and provincial science and technology projects and have received honors such as the "China Patent Gold Award" and the "National Science and Technology Progress Award".
While dedicated to corporate management, Mr. Eric Tse is passionate about and actively involved in youth work in Hong Kong and the Guangdong-Hong-Kong-Macao Greater Bay Area. He frequently speaks out in the Hong Kong media on important topics such as Hong Kong's integration into the national development strategy, the steady and long-term implementation of "One Country, Two Systems", and promoting Hong Kong's transition "from governance to prosperity", contributing to the long-term prosperity, stability, and continued brilliance of Hong Kong.
-
Mr. Eric Tse at the Summer Davos Forum: Deepening Industry-Wide Collaborative Innovation to Drive the Leapfrog Advancement of Biomedicine 2025.06
On June 25, the "Summer Davos Forum" 2025 was held in Tianjin. Premier Li Qiang of the State Council attended the opening ceremony and a symposium with representatives from the business community.View > -
Senior Chairman of Charoen Pokphand Group Mr. Dhanin Chearavanont Attended the 80th Anniversary of the Victory in the Chinese People's War of Resistance, Leaders of CP Pharmaceutical Group Were Invited to Observe the Ceremony 2025.09
On the morning of September 3, a grand ceremony commemorating the 80th anniversary of the victory in the Chinese People's War of Resistance Against Japanese Aggression and the World Anti-Fascist War was held in Tiananmen Square, Beijing.View > -
President of The University of Hong Kong Zhang Xiang and Delegation Visited Chia Tai Tianqing to Explore New Paths for Industry-Academia-Research and Cross-Disciplinary Collaboration 2025.09
On September 6, Zhang Xiang, President of The University of Hong Kong, led a delegation to visit Chia Tai Tianqing, a core enterprise of Sino Biopharm. The delegation included Vice President Lin Chen of The University of Hong Kong and renowned entrepreneurs such as Wang Jianguo, Chairman of Five Star Holdings; Fan Min, Co-founder of Ctrip.com; Wang Zhihan, Chairman of the Board of Goheal Group; and Yang Xiao, Chairman of Renhe Pharmacy Co., Ltd.View > -
Mr. Eric Tse Attended Investor Forum: China's Pharmaceutical Industry Enters a New Development Cycle, Driven by Innovation in R&D and Global Expansion 2025.09
On September 8, the Chief Executive Officer of Sino Biopharm (1177.HK) was invited to attend the 32nd CITIC CLSA Investors' Forum and delivered a speech titled "Sino Biopharm: A Leading Innovation-Driven Pharmaceutical Company," systematically elaborating on the company's achievements and plans in strategic transformation, R&D innovation, and global layout. This forum brought together global industry experts, corporate executives, and top analysts to discuss investment trends and industry dynamics.View > -
Sino Biopharm Reports Strong H1 Results: Net Profit Doubles, Innovation Drives Record Revenue of RMB 17.57 Billion 2025.08
On the afternoon of August 18, Sino Biopharm (1177.HK) held its interim results conference in Hong Kong, continuing its outstanding performance of high growth in revenue and net profit: In the first half of 2025, the company's revenue reached RMB 17.57 billion, with a year-on-year increase of 10.7%; the net profit attributable to owners of the parent from continuing operations was RMB 3.39 billion, with a substantial increase of 140.2%; and the adjusted net profit attributable to owners of the parent was RMB 3.09 billion, with a year-on-year increase of 101.1%.View >